Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Proteomics International Laboratories will receive more than $1.1 million from the Australian Government for the 2018-2019 financial year
  • In 2018 to 2019, the company spent $2.62 million on research and development
  • The company has developed PromarkerD, a predictive test for diabetic kidney disease
  • Proteomics remains steady on the market today and is selling shares for 32.5 cents apiece

Proteomics International Laboratories is set to receive more than $1.1 million from the Australian Government.

The research and development (R&D) tax incentive came from the Australian Government’s Research and Development Tax Incentive Program.

The R&D tax incentive is a rebate business for developing new products and services. It allows businesses to claim back up to 43.5 per cent of the costs related to research and development.

In 2018-2019 Proteomics spent $2.62 million on R&D, making the company eligible for the large rebate.

Proteomics is a medical technology company which developed PromarkerD, a predictive diagnostic test for diabetic kidney disease.

According to the World Health Organisation, diabetes is one of the leading causes of death in the world with about 442 million people worldwide suffering from it.

Proteomics reports one in three adults with diabetes suffer from chronic kidney disease. However, the company believes that with early intervention, diabetic kidney disease can be delayed or prevented entirely.

Earlier in September, Proteomics launched its PromarkerD in Spain.

“As the first country in Europe to adopt the PromarkerD test, Spain would be at the forefront of diabetic kidney disease diagnosis and prevention,” Managing Director Dr Richard Lipscombe told the market in September.

Proteomics remains steady on the market today and is selling shares for 32.5 cents apiece at 11:25 am AEDT.

PIQ by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.